Literature DB >> 21057407

Psychopharmacology of depression and sexual disorders.

Giuseppe Stranieri1.   

Abstract

Sexual dysfunctions as side effects of antidepressant treatments are being reported more and more frequently: they are one of the main reasons of dropout from therapy. These side effects are reported in between 20% and 40% of cases. The aim of this study is to highlight, following the actual evidence from the field of psychopharmacology, how these side effects may not be directly related to the antidepressant treatment; on the contrary we show that, following the observational clinical data obtained in our Mental Health Dept., a careful clinical interview about the sexual behaviour of the patients allows psychotherapy to interact with pharmacotherapy, in order to reduce the drug dosage, or replace it with another drug, and/or to combine an erectile dysfunction treatment with the psychopharmacological therapy. This careful clinical interview about the sexual behavior of the patients will more clearly determine the percentages of sexual dysfunction side effects, and also avoid drop-out from antidepressant therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21057407

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  2 in total

1.  Results of a proof-of-concept, dose-finding, double-blind, placebo-controlled study of RX-10100 (Serdaxin®) in subjects with major depressive disorder.

Authors:  Robert Riesenberg; Joshua Rosenthal; Leslie Moldauer; Christine Peterson
Journal:  Psychopharmacology (Berl)       Date:  2011-12-28       Impact factor: 4.530

2.  Sexuality after breast cancer: need for guideline.

Authors:  Sh Vaziri; F Lotfi Kashani
Journal:  Iran J Cancer Prev       Date:  2012
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.